Prevalence and Trajectory of COVID-19-Associated Hypercoagulability Using Serial Thromboelastography in a South African Population
Table 2
Non-TEG characteristics.
Variables
All patients, n = 41
HC, n = 22
Non-HC, n = 19
value
Age (year)
61 [50–67]
62.5 [51–68]
56 [46–64]
0.22
Female, n (%)
26 (63)
14/42 (34%)
12/41 (29%)
Blood parameters
Haemoglobin (g/dL)
13.2 [11.6–14.2]
12.05 [10.6–14.00]
13.3 [13.00–15.00]
0.06
LDH (U/L)
752 [489–901]
759 [495–842]
651 [489–989]
0.98
D-dimers (mg/L)
0.585 [0.38–1.39]
0.58 [0.38–1.0]
0.96 [0.39–2.12]
0.45
Fibrinogen (mg/dL)
6.7 [5.6–7.8]
6.7 [6–7.9]
6.5 [4.9–7.3]
0.40
Platelets (x 109/L)
249 [195–292]
265 [237–342]
221 [167–280]
0.02
PT (sec)
13.45 [13.0–14.4]
13.9 [13.0–14.4]
13.4 [12.9–14.5]
0.75
aPTT (sec)
25.6 [22.35–30.7]
24.7 [21.9–28.7]
25.85 [23.2–32.0]
0.60
INR
1.11 [1.06–1.19]
1.13 [1.06–1.18]
1.11 [1.06–1.2]
0.90
Enoxaparin, n = 39
n = 39
n = 21
n = 18
0.62
Therapeutic, n (%)
20 (51)
10 (48)
10 (56)
Prophylactic n (%)
19 (49)
11 (52)
8 (44)
Severity
Severe
19 (46)
10 (53)
9 (47)
Critically ill
22 (54)
12 (55)
10 (45)
0.9
SOFA
3 [2–4]
3 [2–4]
2 [2–5]
0.49
SAPS2
22 [18–30]
26 [21–31]
21 [18–27]
0.13
DIC
2 [0–2]
2 [0–2]
2 [0–3]
0.16
SIC
2 [2–3]
2 [2–3]
2 [2–3]
0.87
Mortality, n (%)
18 (43.9)
8 (44.4)
10 (55.6)
0.30
Resolution of hypoxemia by day 10, n (%)
13 (32)
8 (36)
5 (26)
0.49
Statistically significant. Data are expressed as median (interquartile range) or count (percentage). HC hypercoagulable, DM diabetes mellitus, LDH lactate dehydrogenase, PT prothrombin time, aPTT activated partial thromboplastin time, INR international normalised ratio, SOFA sequential organ failure assessment, SAPS2 simplified acute physiology score 2, DIC disseminated intravascular coagulopathy, SIC sepsis-induced coagulopathy.